Immunotherapy in malignant peritoneal mesothelioma (Review)

  • Authors:
    • Sabah Alaklabi
    • Arya Mariam Roy
    • Joseph J. Skitzki
    • Renuka Iyer
  • View Affiliations

  • Published online on: February 22, 2023     https://doi.org/10.3892/mco.2023.2627
  • Article Number: 31
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Over the last decade, there has been a movement in cancer treatment away from cytotoxic therapies toward strategies that enhance the immune system against cancer. Immune checkpoint inhibitors (ICIs) have been incorporated into the treatment regimens for patients with various solid tumors. Mesothelioma trials revealed encouraging efficacy; however, patients with peritoneal mesothelioma are usually excluded, slowing the progress of improving the treatment of this aggressive cancer and compelling oncologist to rely on retrospective studies despite their flaws and limitations. Currently, there is no consensus on the role of ICIs in the treatment of malignant peritoneal mesothelioma (MPeM). The present review discusses data from clinical studies that examined immunotherapy in MPeM and evaluates what is known about the relevance of the tumor microenvironment and clinically validated biomarkers for ICIs efficacy. Furthermore, a proposed strategy for utilizing immunotherapy in treating MPeM is discussed.
View References

Related Articles

Journal Cover

April-2023
Volume 18 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Alaklabi S, Roy AM, Skitzki JJ and Iyer R: Immunotherapy in malignant peritoneal mesothelioma (Review). Mol Clin Oncol 18: 31, 2023.
APA
Alaklabi, S., Roy, A.M., Skitzki, J.J., & Iyer, R. (2023). Immunotherapy in malignant peritoneal mesothelioma (Review). Molecular and Clinical Oncology, 18, 31. https://doi.org/10.3892/mco.2023.2627
MLA
Alaklabi, S., Roy, A. M., Skitzki, J. J., Iyer, R."Immunotherapy in malignant peritoneal mesothelioma (Review)". Molecular and Clinical Oncology 18.4 (2023): 31.
Chicago
Alaklabi, S., Roy, A. M., Skitzki, J. J., Iyer, R."Immunotherapy in malignant peritoneal mesothelioma (Review)". Molecular and Clinical Oncology 18, no. 4 (2023): 31. https://doi.org/10.3892/mco.2023.2627